Cancer cell analysis market seen reaching $17.5 billion by 2030

The global cancer cell analysis market is projected to grow from $11.41 billion in 2025 to $17.5 billion by 2030, driven by AI-assisted imaging, single-cell technologies and demand for personalized oncology. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Cancer cell analysis supports earlier detection, more accurate diagnosis and tailored treatment planning for cancer patients. - Growth in this market reflects broader demand for precision oncology tools that can reveal tumor biology, cellular heterogeneity and treatment response. - Rising research spending could accelerate biomarker discovery and targeted therapy development.

What happened: - The Business Research Company published a cancer cell analysis market report on July 29, 2026. - The report projects the market will rise from $11.41 billion in 2025 to $12.45 billion in 2026. - The report forecasts the market will reach $17.5 billion by 2030. - The report cites a 9.2% CAGR for 2025-2026 and an 8.9% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - The report links recent growth to rising cancer prevalence, limits in traditional diagnostic methods, weak early-detection tools, slow adoption of multi-omics strategies and thin research infrastructure. - The forecast period is being driven by AI-assisted imaging and analysis, single-cell technologies, multi-omics platforms, high-throughput screening and demand for personalized oncology and precision medicine. - The report highlights AI-based cancer cell imaging, multi-omics integration, single-cell analysis innovations and improved high-throughput screening as key trends. - Cancer cell analysis uses laboratory and imaging technologies to examine cancer cells’ structure, behavior and genetic features. - The market overview covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says its 2026 editions add market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report includes key technologies and future trend analysis. - The report offers a free sample at the sample report. - The full report is available at the market report.

Between the lines: - The market outlook suggests cancer analysis is shifting from a diagnostics category toward a data-heavy precision medicine workflow. - The emphasis on AI, single-cell and multi-omics tools points to a competitive race around higher-resolution cancer profiling. - The funding example from the National Cancer Institute shows public investment remains a key demand driver. - The NCI allocated $7.2 billion for cancer research in fiscal year 2024, up 1.7% from 2023.

What's next: - Research and healthcare providers are likely to keep adopting AI-enabled and multi-omics tools as cancer diagnostics and therapy selection become more personalized. - Regional growth may continue to shift toward Asia-Pacific as healthcare access and research activity expand. - The market’s next milestone is the projected $17.5 billion size by 2030.